Alzheimer’s with Agitation
Northern California Research is conducting a phase 2 clinical research study to evaluate the safety and efficacy of the study medication AXS-05 (105 mg bupropion/30mg-45mg dextromethorphan) for the treatment of Agitation in patients with Dementia of the Alzheimer’s type.
You may be eligible if you:
- Have a diagnosis of probable Alzheimer’s Disease
- Have a Caregiver who is a family member who has been providing care for at least 3 months prior and has a minimum of 16 hours of physical contact with the patient a week
- Has had symptoms of Significant Agitation for at least 2 week
- Includes: Physical, Verbal, and Excessive Motor Activity aggression
The trial doctor will review other eligibility criteria with you. This study is 10 weeks long and includes 7 office visits. All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for both the patient and caregiver for trial-related time and travel may be provided.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03226522